- Altasciences has entered into a collaboration with Evidence Matters to apply advanced AI technology to clinical trial documentation.
- The partnership will combine Altasciences’ drug development expertise with Evidence Matters’ Text Engineering and RegulatoryFlow platform to improve the quality, speed, and accuracy of regulatory writing.
Altasciences, a contract research and contract development and manufacturing organisation (CRO/CDMO), has announced a strategic collaboration with Evidence Matters, a company specialising in clinical trial data science and document engineering.
The partnership centres on Evidence Matters’ patent-pending Text Engineering technology and RegulatoryFlow platform, designed to unify clinical data, simplify workflows, and accelerate regulatory writing. According to Altasciences, the collaboration will reduce variability in documentation while improving quality, consistency, and efficiency.
Nicole Maciolek, Vice President, Research Services at Altasciences, said: “Through this partnership, we’re not just implementing AI, we’re actively shaping its future as an indispensable tool in life sciences.”
Altasciences is contributing real-world training data and user testing to refine the platform and ensure alignment with industry requirements. Evidence Matters reported that RegulatoryFlow has demonstrated the elimination of table transfer errors and a reduction in processing time by more than 50 per cent compared with manual methods.
The two companies state that the technology integrates directly with Microsoft Word, enabling faster deployment compared with traditional enterprise platforms. They aim to accelerate clinical trial implementation and documentation, helping sponsors advance from candidate selection to proof of concept with greater speed and accuracy.
